DAF-shielded Baculovirus-vectored Vaccine Enhances Protection Against Malaria Sporozoite Challenge in Mice

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2017 Oct 1

PMID 28962615

Citations 11

Authors

Mitsuhiro Iyori

Daisuke S Yamamoto

Miako Sakaguchi

Masanori Mizutani

Sota Ogata

Hidesato Nishiura

Takahiko Tamura

Hiroyuki Matsuoka

Shigeto Yoshida

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have shown that the baculovirus-vectored vaccine based on the "baculovirus dual expression system (BDES)" is an effective vaccine delivery platform for malaria. However, a point of weakness remaining for use of this vaccine platform in vivo concerns viral inactivation by serum complement. In an effort to achieve complement resistance, the gene encoding the human decay-accelerating factor (hDAF) was incorporated into the BDES malaria vaccine expressing the Plasmodium falciparum circumsporozoite protein (PfCSP).

Results: The newly-developed BDES vaccine, designated BDES-sPfCSP2-Spider, effectively displayed hDAF and PfCSP on the surface of the viral envelope, resulting in complement resistance both in vitro and in vivo. Importantly, upon intramuscular inoculation into mice, the BDES-sPfCSP2-Spider vaccine had a higher protective efficacy (60%) than that of the control vaccine BDES-sPfCSP2-Spier (30%) against challenge with transgenic Plasmodium berghei sporozoites expressing PfCSP.

Conclusion: DAF-shielded BDES-vaccines offer great potential for development as a new malaria vaccine platform against the sporozoite challenge.

Citing Articles

A Head-to-Head Comparative Study of the Replication-Competent Vaccinia Virus and AAV1-Based Malaria Vaccine versus RTS,S/AS01 in Murine Models.

Zainal K, Hasyim A, Yamamoto Y, Mizuno T, Sato Y, Rasyid S Vaccines (Basel). 2024; 12(10).

PMID: 39460322 PMC: 11512279. DOI: 10.3390/vaccines12101155.

A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.

Caillava A, Alfonso V, Cibello M, Demaria M, Coria L, Cassataro J J Virol. 2024; 98(11):e0101724.

PMID: 39440961 PMC: 11575139. DOI: 10.1128/jvi.01017-24.

Baculovirus Display of Peptides and Proteins for Medical Applications.

Rodriguez-Hernandez A, Martinez-Flores D, Cruz-Resendiz A, Padilla-Flores T, Gonzalez-Flores R, Estrada K Viruses. 2023; 15(2).

PMID: 36851625 PMC: 9962271. DOI: 10.3390/v15020411.

Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study.

Iyori M, Blagborough A, Mizuno T, Abe Y, Nagaoka M, Hori N Front Immunol. 2022; 13:1005476.

PMID: 36248835 PMC: 9558734. DOI: 10.3389/fimmu.2022.1005476.

Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 of .

Kim M, Chu K, Kang H, Yoon K, Eom G, Mao J Biomedicines. 2022; 10(9).

PMID: 36140395 PMC: 9496152. DOI: 10.3390/biomedicines10092289.

References

Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto D, Kawasaki M . Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One. 2013; 8(8):e70819. PMC: 3741388. DOI: 10.1371/journal.pone.0070819. View

Ishizuka A, Lyke K, DeZure A, Berry A, Richie T, Mendoza F . Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016; 22(6):614-23. PMC: 11294733. DOI: 10.1038/nm.4110. View

Yoshida S, Kondoh D, Arai E, Matsuoka H, Seki C, Tanaka T . Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. Virology. 2003; 316(1):161-70. DOI: 10.1016/j.virol.2003.08.003. View

Liszewski M, Post T, Atkinson J . Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol. 1991; 9:431-55. DOI: 10.1146/annurev.iy.09.040191.002243. View

Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365(20):1863-75. DOI: 10.1056/NEJMoa1102287. View

Epstein J, Paolino K, Richie T, Sedegah M, Singer A, Ruben A . Protection against malaria by PfSPZ Vaccine. JCI Insight. 2017; 2(1):e89154. PMC: 5214067. DOI: 10.1172/jci.insight.89154. View

Frevert U, Sinnis P, Cerami C, Shreffler W, TAKACS B, NUSSENZWEIG V . Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med. 1993; 177(5):1287-98. PMC: 2190997. DOI: 10.1084/jem.177.5.1287. View

Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M . Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med. 2016; 374(26):2519-29. PMC: 4962898. DOI: 10.1056/NEJMoa1515257. View

Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M . A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun. 2009; 77(5):1782-9. PMC: 2681746. DOI: 10.1128/IAI.01226-08. View

10.

Sala K, Nishiura H, Upton L, Zakutansky S, Delves M, Iyori M . The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro. Vaccine. 2014; 33(3):437-45. DOI: 10.1016/j.vaccine.2014.11.038. View

11.

Yoshida S, Araki H, Yokomine T . Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun. 2009; 78(2):595-602. PMC: 2812197. DOI: 10.1128/IAI.00877-09. View

12.

Blagborough A, Yoshida S, Sattabongkot J, Tsuboi T, Sinden R . Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine. 2010; 28(37):6014-20. DOI: 10.1016/j.vaccine.2010.06.100. View

13.

Kaikkonen M, Maatta A, Yla-Herttuala S, Airenne K . Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery. Mol Ther. 2010; 18(5):987-92. PMC: 2890102. DOI: 10.1038/mt.2010.25. View

14.

Nicholson-Weller A, Wang C . Structure and function of decay accelerating factor CD55. J Lab Clin Med. 1994; 123(4):485-91. View

15.

Lyke K, Ishizuka A, Berry A, Chakravarty S, DeZure A, Enama M . Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017; 114(10):2711-2716. PMC: 5347610. DOI: 10.1073/pnas.1615324114. View

16.

Hofmann C, Strauss M . Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998; 5(4):531-6. DOI: 10.1038/sj.gt.3300607. View

17.

Lin S, Chung Y, Hu Y . Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines. 2014; 13(12):1501-21. DOI: 10.1586/14760584.2014.951637. View

18.

Cerami C, Frevert U, Sinnis P, TAKACS B, Clavijo P, Santos M . The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell. 1992; 70(6):1021-33. DOI: 10.1016/0092-8674(92)90251-7. View

19.

Tamura T, Kawabata C, Matsushita S, Sakaguchi M, Yoshida S . Malaria sporozoite protein expression enhances baculovirus-mediated gene transfer to hepatocytes. J Gene Med. 2016; 18(4-6):75-85. DOI: 10.1002/jgm.2879. View

20.

Huser A, Rudolph M, Hofmann C . Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol. 2001; 19(5):451-5. DOI: 10.1038/88122. View